Aberdeen Group plc Grows Stock Holdings in Vericel Corporation $VCEL

Aberdeen Group plc lifted its stake in Vericel Corporation (NASDAQ:VCEL) by 159.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 542,866 shares of the biotechnology company’s stock after purchasing an additional 333,649 shares during the quarter. Aberdeen Group plc owned about 1.08% of Vericel worth $17,084,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Russell Investments Group Ltd. grew its holdings in Vericel by 38.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 118,856 shares of the biotechnology company’s stock valued at $5,057,000 after buying an additional 32,976 shares in the last quarter. Frontier Capital Management Co. LLC increased its holdings in shares of Vericel by 74.3% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 398,960 shares of the biotechnology company’s stock worth $16,976,000 after buying an additional 170,006 shares during the last quarter. Summit Creek Advisors LLC raised its position in shares of Vericel by 35.1% during the 3rd quarter. Summit Creek Advisors LLC now owns 531,603 shares of the biotechnology company’s stock valued at $16,730,000 after buying an additional 138,124 shares during the period. Atria Investments Inc lifted its holdings in Vericel by 44.3% in the second quarter. Atria Investments Inc now owns 10,273 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 3,154 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in Vericel in the second quarter worth approximately $204,000.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on VCEL. Zacks Research cut shares of Vericel from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Truist Financial dropped their target price on shares of Vericel from $50.00 to $45.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Weiss Ratings restated a “hold (c-)” rating on shares of Vericel in a research note on Monday, December 29th. Finally, Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a research note on Sunday, January 25th. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $57.50.

Vericel Price Performance

NASDAQ VCEL opened at $37.41 on Thursday. The company has a market cap of $1.89 billion, a P/E ratio of 155.88 and a beta of 1.24. Vericel Corporation has a 1-year low of $29.24 and a 1-year high of $58.16. The stock has a 50-day moving average of $36.93 and a two-hundred day moving average of $36.08.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.